Investor Relations : BioMarin

Investors & Media

Stock Quote

NASDAQBMRN

Events

First Gene Therapy for Adults with Severe Hemophilia A, BioMarin’s ROCTAVIAN™ (valoctocogene roxaparvovec), Approved by European Commission (EC) Webcast

Wednesday, August 24, 2022

5:00pm PDT

All Events

Press Releases

Email Alerts

Sep 15, 2022

BioMarin's Gene Therapy for Adults with Severe Hemophilia A, ROCTAVIAN™ (valoctocogene roxaparvovec), Assessed to Provide Substantial Cost Savings Per Patient in a Preliminary Independent Report

Institute for Clinical and Economic Review (ICER) Base-Case Model Report Results in $4 Million Savings Versus Emicizumab Prophylaxis Per Patient Over a Lifetime Biologics License Application (BLA)...

All Press Releases

Quarterly Results

Doc

BioMarin Announces Record Revenues in Second Quarter 2022

Call

Listen to the 2Q22 CC Replay

All Financial Information

click here for R&D Day slides

View the Presentation

Investor Resources

A commitment to corporate responsibility.

We are committed to conducting our operations and managing our products in a responsible manner and in accordance with applicable laws, rules, and regulations. We regularly review our operations to improve efficiency and reduce environmental impact where appropriate.

Learn More

We take on the biggest challenges in rare disease.

Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address.

Learn More

Investor Relations
415-455-7558
IR@BMRN.com

Media & Press
415-455-7451
corporatecommunications2@BMRN.com

Email Alerts